Quest Diagnostics now offers BRCAvantage Plus™ expanded testing for significant breast cancer susceptibility genes.
Why test beyond BRCA1 and BRCA2?
While mutations in BRCA1 and BRCA2 may explain 15-20% of hereditary breast cancer cases1, TP53, PTEN, CDH1, STK11 and PALB2 have also been described as high penetrance cancer susceptibility genes and together explain an additional 3.0-4.5% of hereditary breast cancers.
This complimentary, web-based program, supported by an independent medical education grant from Quest Diagnostics, provides clinicians with the opportunity to earn CME credit while learning how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in the diagnosis and management of breast cancer.
Quest Diagnostics and Inserm, the French National Institute of Health and Medical Research, are proud to announce they have co-founded BRCA Share™ providing scientists, academic institutions and commercial laboratories around the world with access to BRCA1 and BRCA2 genetic data.
The program’s goal is to accelerate research on BRCA gene mutations to improve the ability of clinical laboratory diagnostics topredict which individuals are at risk of developing these cancers.
BRCAvantage™ combines testing expertise with extensive support services to deliver results you can trust: